Cargando…
Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers
Since arsenic trioxide was first approved as the front line therapy for acute promyelocytic leukemia 25 years ago, its anti-cancer properties for various malignancies have been under intense investigation. However, the clinical successes of arsenic trioxide in treating hematological cancers have not...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Editorial Department of Journal of Biomedical Research
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460606/ https://www.ncbi.nlm.nih.gov/pubmed/28808212 http://dx.doi.org/10.7555/JBR.31.20160059 |